Dova Pharmaceuticals Aktie (0AV)

Aktien-News

Tops/Flops

Kurs zur DOVA PHARMACEUTI. DL-,001 Aktie

25,40 EUR

±0,00 %±0,00

12. Nov 2019, Berlin

5 haben den Wert in der Watchlist

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.

Chart-Tool

Themen entdecken

Schorsch11, DOVA PHARMACEUTI. … Hauptdiskussion, 01.10.2019 8:37 Uhr

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) announced it will be acquired by Swedish Orphan Biovitrum AB. Dova stockholders will be offered an upfront payment for $27.50 per share in cash, along with one non-tradeable Contingent Value Right (CVR) that entitles them to an additional $1.50 per share in cash upon regulatory approval of Doptelet for the treatment of chemotherapy-induced thrombocytopenia (CIT), representing a total potential consideration of up to $915m. Shares closed up 38% to $27.95.

Schorsch11, DOVA PHARMACEUTI. … Hauptdiskussion, 27.06.2019 14:21 Uhr

DOVA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR DOPTELET® (AVATROMBOPAG) FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new

Schorsch11, DOVA PHARMACEUTI. … Hauptdiskussion, 27.06.2019 9:43 Uhr

As of March 31, 2019, Dova had $92.7 million in cash and equivalents compared to $104.6 million as of December 31, 2018. Additionally, on May 6, 2019, Dova entered into an amended and restated loan agreement with Silicon Valley Bank that extends the interest only period of the existing $20 million loan facility by 12 months and provides additional potential borrowings of $30 million upon achieving certain clinical and revenue milestones. https://finance.yahoo.com/news/dova-pharmaceuticals-reports-first-quarter-110000179.html?.tsrc=rss

Schorsch11, DOVA PHARMACEUTI. … Hauptdiskussion, 27.06.2019 9:41 Uhr

sNDA under review by the U.S. FDA for DOPTELET for the treatment of chronic immune thrombocytopenia (ITP); PDUFA date June 30, 2019

Schorsch11, DOVA PHARMACEUTI. … Hauptdiskussion, 25.06.2019 15:08 Uhr

Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress https://finance.yahoo.com/news/dova-pharmaceuticals-announces-four-presentations-120000016.html?.tsrc=rss

Schorsch11, DOVA PHARMACEUTI. … Hauptdiskussion, 25.06.2019 15:07 Uhr

Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease https://finance.yahoo.com/news/dova-pharmaceuticals-announces-european-union-120000914.html?.tsrc=rss